Fundraising Fox

LB Pharmaceuticals

NASDAQ: LBRX

New York, US · Delaware corporation · 4 known investors

Find your way into LB Pharmaceuticals

70 people in our graph share verified history with the LB Pharmaceuticals team — schools, employers, funds. One of them is your warm intro.

Chris Weyrerunlockedknows Zachary Prensky · together at LB Pharmaceuticals Inc (overlapped)
×11knows the team · via Yeshiva University

A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders. Its lead candidate, LB-102, is an oral benzamide antipsychotic being developed for the U.S. market.

BiotechHealthtech

Founders & leadership

ZPZachary Prensky
Zachary PrenskyinFounderZachary Prensky is co-founder and director of LB Pharmaceuticals, a clinical-stage biopharmaceutical company developing small molecule therapies for neuropsychiatric disorders including schizophrenia and bipolar depression; he previously managed a family office focused on biotechnology investments and is a named inventor on patents related to the company's lead candidate, LB-102.
LS
Lauren StippExecutive
MP
Mark PanoffExecutive
HT
Heather TurnerPresident & Chief Executive Officer and Director
GS
Gad SofferChief Operating and Business Officer
AE
Anna EramoChief Medical Officer
KP
Kaya Pai PanandikerinChief Commercial Officer

Board

ES
Edmund SullivanBoard director
VG
Vincent GrattanBoard director

Investors · 4

Pontifax Venture CapitalHerzeliya · $6.3M – $128M
Tarnagulla VenturesMelbourne
Vida VenturesLos Angeles
TCG Crossoverreported · 2 sourcesPalo Alto

Reported raises · per SEC filings

Form D private placements

$141.4M disclosed across 9 rounds · 2016–2023

▶$110.7MraisedJan 2024 · 6 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Rajul JainDirector
  • Ran NussbaumDirector
  • Zachary PrenskyExecutive Officer, Director
  • Robert RuffoloDirector
  • Andrew VainoExecutive Officer
  • Anna EramoExecutive Officer
  • Marc PanoffExecutive Officer
  • Rebecca LuseDirector
  • Chen YuDirector
Offering amount
$110.7M
Amount sold
$110.7M
Sales commissions
$2.5M
Finders' fees
$735K
Proceeds to insiders
$1.3M
Placement agents
Agile Capital Markets, Maxim Group LLC
First sale
Aug 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$16.6MraisedNov 2022 · 71 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Edmund SullivanDirector
  • Vincent GrattanDirector
  • Piero PoliDirector
  • Zachary PrenskyExecutive Officer, Director
  • Marc PanoffExecutive Officer
  • Robert RuffoloDirector
Offering amount
$40M
Amount sold
$16.6M
Minimum investment
$25K
Sales commissions
$1.7M
Proceeds to insiders
$437.2K
Placement agents
Maxim Group LLC
First sale
Oct 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$903.4KraisedJul 2022 · 35 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Robert RuffoloDirector
  • Marc PanoffExecutive Officer
  • Vincent GrattanDirector
  • Edmund SullivanDirector
  • Piero PoliDirector
  • Zachary PrenskyExecutive Officer, Director
Amount sold
$903.4K
Sales commissions
$85.9K
Proceeds to insiders
$115K
Placement agents
Maxim Group LLC
First sale
May 2022
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.6MraisedSep 2020 · 35 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Piero PoliDirector
  • Vincent GrattanDirector
  • Edmund SullivanDirector
  • Marc PanoffExecutive Officer
  • Robert RuffoloDirector
  • Zachary PrenskyExecutive Officer, Director
Offering amount
$10M
Amount sold
$4.6M
Minimum investment
$10K
Sales commissions
$455.4K
Proceeds to insiders
$454K
Placement agents
Maxim Group LLC
First sale
Aug 2020
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.3MraisedDec 2018 · 74 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Marc PanoffExecutive Officer
  • Andrew VainoExecutive Officer
  • Edmund SullivanDirector
  • Vincent GrattanDirector
  • Zachary PrenskyExecutive Officer, Director
Offering amount
$10M
Amount sold
$6.3M
Minimum investment
$25K
Sales commissions
$670.2K
Proceeds to insiders
$550K
Placement agents
Maxim Group LLC
First sale
Nov 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$443.2KraisedAug 2018 · 7 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Zachary PrenskyExecutive Officer, Director
  • Andrew VainoExecutive Officer
  • Vincent GrattanDirector
  • Mark PanoffExecutive Officer
  • Edmund SullivanDirector
Offering amount
$443.2K
Amount sold
$443.2K
Minimum investment
$10K
First sale
Dec 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$330KraisedMay 2018 · 11 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Zachary PrenskyExecutive Officer, Director
  • Andrew VainoExecutive Officer
  • Vincent GrattanDirector
  • Edmund SullivanDirector
  • Mark PanoffExecutive Officer
Offering amount
$750K
Amount sold
$330K
Minimum investment
$10K
Proceeds to insiders
$30K
First sale
May 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$462KraisedApr 2017 · 8 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Edmund SullivanDirector
  • Lauren StippExecutive Officer
  • Mark PanoffExecutive Officer
  • Vincent GrattanDirector
  • Zachary PrenskyExecutive Officer, Director
Offering amount
$462K
Amount sold
$462K
Minimum investment
$10K
First sale
Apr 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Valuation · disclosed

Disclosed events
$336.6Mvaluation at IPOSep 2025 · $15.00/share · 424B4
filing ↗

Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.

Competitors · 3

by search overlap
Seeking Alpha9 shared keywordsSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.
Simply Wall St8 shared keywordsSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.
Robinhood8 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

Companies competing with LB Pharmaceuticals for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does LB Pharmaceuticals do?
A clinical-stage biopharmaceutical company developing small molecule therapies for schizophrenia, bipolar depression, and other neuropsychiatric disorders. Its lead candidate, LB-102, is an oral benzamide antipsychotic being developed for the U.S. market.
Who founded LB Pharmaceuticals?
LB Pharmaceuticals was founded by Zachary Prensky.
Who are LB Pharmaceuticals's investors?
LB Pharmaceuticals's investors include Pontifax Venture Capital, Tarnagulla Ventures, Vida Ventures, TCG Crossover.
How much funding has LB Pharmaceuticals raised?
LB Pharmaceuticals has disclosed $141.4M raised across 9 rounds.
Where is LB Pharmaceuticals headquartered?
LB Pharmaceuticals is headquartered in New York, US.